Maruti Suzuki, RailTel Corporation and Greaves Cotton to see some action today

Maruti Suzuki India has signed a five-year agreement with Kamarajar Port for export of its passenger vehicles to international markets. Under the agreement starting December 2022, Kamarajar Port will be used for exports to Africa, Middle East, Latin America, ASEAN, Oceania and SAARC regions by the company.

RailTel Corporation of India has bagged the work order from Webel Technology for acting as System Integrator for Capacity Enhancement of West Bengal State Data Centre (WB-SDC), Monibhandar, Kolkata. The total value of the work is Rs 98.56 crore (including GST).

Greaves Electric Mobility (GEMPL), the e-mobility business of Greaves Cotton, has adopted the Siemens Xcelerator portfolio of software and services to design, and develop its electric two & threewheeler vehicles for the Indian market. The initiative re-affirms Greaves’ vision to popularize EV adoption and bring affordable, sustainable, last mile mobility to India’s rapidly burgeoning EV ecosystem.

Mahindra Lifespace Developers has completed the acquisition of a 9.24-acre land parcel in Mumbai from Mahindra & Mahindra for Rs 365 crore. In February this year, Mahindra Lifespace had announced that it would purchase the land in Kandivali, Mumbai from Mahindra & Mahindra Ltd for the development of a housing project.

Rail Vikas Nigam (RVNL) has been awarded contract for Construction of Bhesan Depot cum Workshop which includes DDC, BCC and associated E&M works under Corridor- C2, Bhesan to Saroli, for Surat Metro Rail Project Phase- 1, DC 2 by Gujarat Metro Rail Corporation (GMRC). The total awarded cost of project is Rs 198.93 crore (Excluding taxes, duties and Provisional Sum).

Spandana Sphoorty Financial has raised Rs 65 crore through allotment of 650 Secured, Rated, Listed, Redeemable, Non-Convertible Debentures (NCDs) having face value of Rs 10,00,000 each, at par, on a private placement basis in demat form. The Management Committee of the Board of Directors of the Company vide its resolution dated December 22, 2022, has approved and allotted the same.

Lupin Pharmaceuticals Inc., the U.S. based wholly-owned subsidiary of Lupin, is voluntarily recalling four lots of Quinapril Tablets to the patient (consumer/user) level due to the presence of a nitrosamine impurity, N-Nitroso-Quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. To date, Lupin has received no reports of illness that appear to relate to this issue. Lupin discontinued the marketing of Quinapril tablets in September 2022.